share_log

Novavax | 4: Statement of changes in beneficial ownership of securities-Officer Dubovsky Filip

Novavax | 4: Statement of changes in beneficial ownership of securities-Officer Dubovsky Filip

诺瓦瓦克斯医药 | 4:持股变动声明-高管 Dubovsky Filip
美股SEC公告 ·  05/16 09:21

Moomoo AI 已提取核心信息

On May 14, 2024, Novavax's President of R&D, Filip Dubovsky, completed a significant transaction involving the company's common stock. Dubovsky executed a sale of 47,312 shares at a price of $13.90 per share, resulting in a total market value of $657,636.80. Prior to this sale, Dubovsky acquired 19,652 shares through the exercise of derivative securities at a price of $6.97 each. Following these transactions, Dubovsky's direct holdings in Novavax amounted to 38,953 shares of common stock.
On May 14, 2024, Novavax's President of R&D, Filip Dubovsky, completed a significant transaction involving the company's common stock. Dubovsky executed a sale of 47,312 shares at a price of $13.90 per share, resulting in a total market value of $657,636.80. Prior to this sale, Dubovsky acquired 19,652 shares through the exercise of derivative securities at a price of $6.97 each. Following these transactions, Dubovsky's direct holdings in Novavax amounted to 38,953 shares of common stock.
2024年5月14日,Novavax的研发总裁菲利普·杜波夫斯基完成了一项涉及公司普通股的重大交易。杜波夫斯基以每股13.90美元的价格出售了47,312股股票,总市值为657,636.80美元。在此次出售之前,杜波夫斯基通过行使衍生证券以每股6.97美元的价格收购了19,652股股票。这些交易之后,杜波夫斯基在Novavax的直接持有量为38,953股普通股。
2024年5月14日,Novavax的研发总裁菲利普·杜波夫斯基完成了一项涉及公司普通股的重大交易。杜波夫斯基以每股13.90美元的价格出售了47,312股股票,总市值为657,636.80美元。在此次出售之前,杜波夫斯基通过行使衍生证券以每股6.97美元的价格收购了19,652股股票。这些交易之后,杜波夫斯基在Novavax的直接持有量为38,953股普通股。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息